Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-10
2006-10-10
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07119103
ABSTRACT:
The invention provides β3-adrenoreceptor agonists, pharmaceutical compositions comprising β3-adrenoreceptor agonist compounds, and methods of using such compounds for stimulating, regulating or modulating metabolism of fats in adipose tissue in animals.
REFERENCES:
patent: 3337539 (1967-08-01), Mészáros et al.
patent: 3438989 (1969-04-01), Shavel, Jr. et al.
patent: 3497516 (1970-02-01), Mashimo et al.
patent: 3647799 (1972-03-01), Watanabe et al.
patent: 3818015 (1974-06-01), Yamato et al.
patent: 3872130 (1975-03-01), Kreighbaum et al.
patent: 3873704 (1975-03-01), Yamato et al.
patent: 3910915 (1975-10-01), Yonan
patent: 3910927 (1975-10-01), Kreighbaum et al.
patent: 3988339 (1976-10-01), Kaiser et al.
patent: 4054659 (1977-10-01), Ikezaki et al.
patent: 4321254 (1982-03-01), Ali
patent: 4442108 (1984-04-01), Le Polles et al.
patent: 4525589 (1985-06-01), Hidaka et al.
patent: 4536510 (1985-08-01), Wasserman et al.
patent: 4666918 (1987-05-01), Ivanova et al.
patent: 4707485 (1987-11-01), Kaiser et al.
patent: 4737504 (1988-04-01), Miller et al.
patent: 4798897 (1989-01-01), Hidaka et al.
patent: 4812573 (1989-03-01), Durant et al.
patent: 4857301 (1989-08-01), Czarniecki et al.
patent: 5059608 (1991-10-01), Takasugi et al.
patent: 5177085 (1993-01-01), Naef
patent: 5210088 (1993-05-01), Minchin et al.
patent: 5238935 (1993-08-01), Dugar et al.
patent: 5246943 (1993-09-01), Blankley et al.
patent: 5272270 (1993-12-01), Hirsenkorn et al.
patent: 5340811 (1994-08-01), Kajihara et al.
patent: 5350757 (1994-09-01), Blankley et al.
patent: 5362736 (1994-11-01), Ishikawa et al.
patent: 5446164 (1995-08-01), Ishikawa et al.
patent: 5498717 (1996-03-01), Ishikawa et al.
patent: 5519034 (1996-05-01), Kozlik et al.
patent: 5525614 (1996-06-01), Blankley et al.
patent: 5707985 (1998-01-01), McKenzie et al.
patent: 5750520 (1998-05-01), Danilewicz et al.
patent: 5756516 (1998-05-01), Liu et al.
patent: 5798352 (1998-08-01), Danilewicz
patent: 5804586 (1998-09-01), Sargent et al.
patent: 5807868 (1998-09-01), Sargent et al.
patent: 5880285 (1999-03-01), Broger et al.
patent: 5929085 (1999-07-01), MacDonald et al.
patent: 6043253 (2000-03-01), Brockunier et al.
patent: 6063925 (2000-05-01), Demian et al.
patent: 6127381 (2000-10-01), Basu et al.
patent: 6153608 (2000-11-01), Hidaka et al.
patent: 6248754 (2001-06-01), Coulton et al.
patent: 6274594 (2001-08-01), Coulton et al.
patent: 6277861 (2001-08-01), Harling et al.
patent: 2001/0039289 (2001-11-01), Blok et al.
patent: 0 210 827 (1987-02-01), None
patent: 47018898 (1972-09-01), None
patent: 52095676 (1977-08-01), None
patent: WO 99/44609 (1999-09-01), None
Adejare, et al., “Syntheses and β-Adrenergic Agonist and Antiaggregatory Properties of N-Substituted Trimetoquinol Analogues1”,J. Med. Chem., 1986, pp. 1603-1609, vol. 29.
Ahn, et al., “Characterization of the Inhibition of U46619-Mediated Human Platelet Activation by the Trimetoquinol Isomers”,Biochemical Pharmacology, 1988, pp. 3023-3033, vol. 37, No. 15.
Christoff, et al., “Snythesis and Evaluation of Trimetoquinol Derivatives: Novel Thromboxane A2/Prostaglandin H2Antagonists with Diminished β-Adrenergic Agonist Activity”,J. Med. Chem., 1997, vol. 40, pp. 85-91.
Clark, et al., “5-Fluoro- and 8-Fluorotrimetoquinol: Selective β2-Adrenoceptor Agonists”,J. Med. Chem., 1987, pp. 86-90, vol. 30.
De Los Angeles, et al., “Iodinated Analogs of Trimetoquinol as Highly Potent and Selective β2-Adrenoceptor Ligands”,J. Med. Chem., 1996, vol. 39, pp. 3701-3711.
Fraundorfer, et al., “Biochemical and Pharmacological Characterization of High-Affinity Trimetoquinol Analogs on Guinea Pig and Human Beta Adrenergic Receptor Subtypes: Evidence for Partial Agonism1”,J. Pharmacology and Experimental Therapeutics, 1994, pp. 665-674, vol. 270, No. 2.
Fraundorfer, Paul F., “Functional and Biochemical Characterization of Trimetoquinol (TMQ) Analog Interactions with β-Adrenergic Receptor Subtypes”, A Dissertation, The Ohio State University, 1993.
Harrold, et al., “Synthesis and Platelet Antiaggregatory Activity of Trimetoquinol Analogs as Endoperoxide/Thromboxane A2Antagonists”,Drug Design and Delivery, 1987, pp. 193-207, vol. 1.
He, et al., “Synthesis and Human β-Adrenoceptor Activity of 1,2,3,4-Tetrahydroisoquinoline-6-ol Derivatives, In Vitro”,Am. Chem. Soc., 218thACS National Meeting, Aug. 22-26, 1999, Abstract.
Howe, Ralph, “β3-Adrenergic agonists”,Drugs of the Future, 1993, pp. 529-549, vol. 18, No. 6.
Ishiwata, et al., “Syntheses of Aminoisoquinolines and Related Compounds. II. Syntheses of 6-amino-1-benzylisoquinolines by the Bischler-Napieralski reaction”,Chem. Pharm. Bull., 1969, vol. 17(11), Abstract.
Ishiwata, et al., “Syntheses of Aminoisoquinolines and Related Compounds. VI. A Modified Synthesis of dl-pronuciferine”,Chem. Pharm. Bull., 1970, vol. 18(6), Abstract.
Ishiwata, et al., “Synthesis of Aminoisoquinolines and Related Compounds. IX. Synthesis of (+-)-0- methylcaseadine”,Chem. Pharm. Bull., 1970, vol. 18(9), Abstract.
Iwasawa, et al., Studies on Tetrahydroisoquinolines (THI) (I) Bronchodilator Activity and Structure- Activity Relationship,Jap. J. Pharmacol., 1967, pp. 143-152, vol. 17.
Kajigaeshi, et al., Halogenation Using Quatemary Ammonium Polyhalides. VII.1)Iodination of Aromatic Amines by Use of Benzyltrimethylammonium Dichloroiodate(1-),Bull. Chem. Soc. Jpn., 1988, pp. 600-602, vol. 61, No. 2.
Konkar A. et al., “Pharmacological activities of trimetoquinol and l -benzyl halogen-substituted analogues on rat β-adrenoceptor subtypes”,European Journal of Pharmacology, 1996, pp. 63-71, vol. 305.
Mayo, et al., “Stereo-Dependent Inhibition of Human Platelet Function by the Optical Isomers of Trimetoquinol”,Biochemical Pharmacology, 1981, pp. 2237-2241, vol. 30, No. 16.
Memetzidis, et al., “Synthesis of Aromatic Chloroberbines”,Heterocycles, 1990, vol. 31(2), Abstract.
Nikulin et al., “A Shortened Approach to Parallel Synthesis of Tetrahydroisoquinolines (THI) Via Bishler- Napieralski Cyclization”,Am. Chem. Soc., 215thACS National Meeting, Mar. 29-Apr. 2, 1998.
Shin, et al., “Interactions of Nonprostanoid Trimetoquinol Analogs with Thromboxane A2/Prostaglandin H2Receptors in Human Platelets, Rat Vascular Endothelial Cells and Rat Vascular Smooth Muscle Cells1”,J. Pharmacology and Experimental Therapeutics, 1993, pp. 1017-1023, vol. 267, No. 3.
Shin, et al., “Pharmacologic Antagonism of Thromboxane A2Receptors by Trimetoquinol Analogs In Vitro and In Vivo”,Chirality, 1991, pp. 112-117, vol. 3.
Shin, et al., “Stereospecific Interactions of Nonprostanoid Trimetoquinol Analogs With Thromboxane A2/Prostaglandin H2Receptor Sites in Human and Rat Platelets, and Rat Vascular Endothelial and Smooth Muscle Cells”,Pharmacology Communications, 1992, pp. 303-312, vol. 1, No. 4.
Yamato, et al., “Synthesis of 6,7-Dihydroxy-1,2,3,4-Tetrahydroisoquinoline Derivatives”,Tetrahedron, 1966, pp. 129-134, Suppl. 8, Part 1.
Zheng, et al., “2-Amino-4-Aryl-4,5,6,7-Tetrahydrothiazolo[5,4-c]Pyridines: Proposed Novel Catechol Bioisosteric Analogs of Trimetoquinol (TMQ)—A Potent β-Adrenoceptor Agonist and TP Receptor Antagonist”,Am. Chem. Soc., 1995 Joint Southeast-Southwest Regional Meeting, Nov. 29-Dec. 1, 1995, Abstract.
Feller Dennis R.
Miller Duane D.
Alston & Bird LLP
Dentz Bernard
Molecular Design International Inc.
LandOfFree
β 3 -Adrenoreceptor agonists, agonist compositions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with β 3 -Adrenoreceptor agonists, agonist compositions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and β 3 -Adrenoreceptor agonists, agonist compositions and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3628983